Pfizer Inc. (NYSE:PFE) is Bard Financial Services Inc.’s 6th Largest Position

Bard Financial Services Inc. reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 29.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 366,424 shares of the biopharmaceutical company’s stock after selling 149,939 shares during the quarter. Pfizer makes up 2.2% of Bard Financial Services Inc.’s holdings, making the stock its 6th largest position. Bard Financial Services Inc.’s holdings in Pfizer were worth $10,604,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Silverberg Bernstein Capital Management LLC purchased a new stake in Pfizer in the third quarter valued at about $252,000. Quent Capital LLC raised its stake in Pfizer by 15.0% in the third quarter. Quent Capital LLC now owns 15,252 shares of the biopharmaceutical company’s stock valued at $442,000 after buying an additional 1,987 shares during the last quarter. Inspirion Wealth Advisors LLC raised its stake in Pfizer by 0.8% in the third quarter. Inspirion Wealth Advisors LLC now owns 52,377 shares of the biopharmaceutical company’s stock valued at $1,516,000 after buying an additional 420 shares during the last quarter. Mirador Capital Partners LP raised its stake in Pfizer by 253.3% in the third quarter. Mirador Capital Partners LP now owns 34,416 shares of the biopharmaceutical company’s stock valued at $996,000 after buying an additional 24,674 shares during the last quarter. Finally, Allied Investment Advisors LLC raised its stake in Pfizer by 3.7% in the third quarter. Allied Investment Advisors LLC now owns 259,203 shares of the biopharmaceutical company’s stock valued at $7,501,000 after buying an additional 9,223 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Pfizer stock traded up $0.24 during midday trading on Friday, hitting $28.58. 28,786,884 shares of the company were exchanged, compared to its average volume of 37,384,395. The firm has a market capitalization of $161.95 billion, a PE ratio of -476.33, a price-to-earnings-growth ratio of 1.25 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92. The business has a fifty day simple moving average of $29.17 and a two-hundred day simple moving average of $28.31. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same period last year, the company earned $0.67 earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on PFE shares. UBS Group increased their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com lowered Pfizer from a “buy” rating to a “hold” rating in a report on Tuesday. Wells Fargo & Company increased their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Nine research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.